Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, shared a post on X by Fabio Arcidiacono, Radiation Oncologist at the “S. Maria” Hospital, Terni, adding:
“My favorite part of the START-NEW-ERA study is that they use both SIB and SIP.
Simultaneous integrated boost
and
Simultaneous integrated protection.”
Quoting Fabio Arcidiacono’s post:
“WCLC25, an honor to present STARTNEWERA and STARTNEWERAOLIGO 🇮🇹trials
OC: ChT – SAbR – IO 35 unresectable LA-NSCLC
OC: SAbR 90 oligoP NSCLC IO TT era
Poster: salvage SAbR 31 thoracic nodal recurrence
Poster discussed: update STARTNEWERA 101 unresectable LA-NSCLC.”
More posts featuring Drew Moghanaki.
